Dicerna Earns $5M Milestone as Partner Kyowa Picks up Cancer Drug | GenomeWeb

Dicerna Pharmaceuticals announced this week that it has earned a $5 million milestone payment after partner Kyowa Hakko Kirin decided to further develop an oncology drug candidate covered by the companies' drug-development alliance.

Kyowa's move comes after the Dicer-substrate drug, which is formulated using Kyowa's proprietary antibody-based delivery technology, demonstrated the ability to trigger complete tumor regression in an animal model of an undisclosed human cancer, Dicerna said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.